New treatments for HIV-1 in patients with tuberculosis in South Africa
Official title: Second Generation InSTIs for the Treatment of HIV-1 in patients with TB co-infection on Rifampicin-based Treatment in KwaZulu Natal, South Africa
Funded at Centre/aids Programme/res/south Africa · NIH-11098825 · Data updated 2026-11-12
This study is looking at how well newer HIV medications, like dolutegravir and bictegravir, work for people with both HIV and tuberculosis, especially in South Africa, to find safe ways to use them together and improve treatment for everyone, including kids and adults.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Centre/aids Programme/res/south Africa NIH-funded |
| Lab location | 1 site (Durban, SOUTH AFRICA) |
| Project start | August 3, 2020 |
| Project end | July 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $285,787 |
| NIH project number | 3R01AI152142-05S2 |
| Project ID | NIH-11098825 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals of all ages, particularly those with HIV-1 who are also being treated for tuberculosis.
✕Less likely to help
Patients who do not have HIV-1 or tuberculosis may not benefit from this research.
What this research studies
This research investigates the effectiveness of second-generation integrase strand transfer inhibitors (InSTIs) like dolutegravir and bictegravir for treating HIV-1 in patients who also have tuberculosis (TB). The study focuses on understanding how these medications can be safely used alongside rifampicin, a common TB treatment, especially in children and adults in South Africa, where HIV and TB co-infection rates are extremely high. By assessing the safety, efficacy, and appropriate dosing of these drugs, the research aims to improve treatment options for patients facing these dual infections.
Why it matters
Potential benefit: If successful, this research could lead to more effective and safer treatment options for patients with HIV-1 and TB co-infection.
How similar studies have gone: Previous research has shown promising results with integrase strand transfer inhibitors in treating HIV, but this specific approach in the context of TB co-infection is novel.
Where this research is happening
-
Centre/aids Programme/res/south Africa
Durban, South Africa Active
Researchers
- Principal investigator: Naidoo, Anushka — Centre/aids Programme/res/south Africa
- Study coordinator: Naidoo, Anushka
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.